Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

The Lancet ◽  
2016 ◽  
Vol 388 (10051) ◽  
pp. 1281-1290 ◽  
Author(s):  
Julián Panés ◽  
Damián García-Olmo ◽  
Gert Van Assche ◽  
Jean Frederic Colombel ◽  
Walter Reinisch ◽  
...  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Víctor Manuel Maciel Gutiérrez ◽  
Sergio Giovanni Gutiérrez Guillen ◽  
Manuel Willebaldo Centeno Flores ◽  
Jesús Alonso Valenzuela Pérez ◽  
Francisco Manuel Abarca Rendón ◽  
...  

2017 ◽  
Vol 153 (1) ◽  
pp. 59-62.e2 ◽  
Author(s):  
Allan B. Dietz ◽  
Eric J. Dozois ◽  
Joel G. Fletcher ◽  
Greg W. Butler ◽  
Darcie Radel ◽  
...  

2019 ◽  
Vol 91 (3) ◽  
pp. 1-5
Author(s):  
Katarzyna Borycka-Kiciak ◽  
Anna Pietrzak ◽  
Maciej Kielar ◽  
Wiesław Tarnowski

Abstract Treatment of perianal fistulizing Crohn’s disease is demanding and burdened with a high percentage of failures, which forces clinicians to search for new, more effective therapeutic options. One of these options is the use of adipose-derived mesenchymal stem cells in local administration. Due to their multipotentiality and complex mechanism of action, stem cells are the promising new therapeutic approach for the treatment-refractory complex perianal fistulas - demonstrating both high efficacy and a favorable safety profile. The paper presents current knowledge on the mechanisms of action and manner of administration of mesenchymal stem cells, as well as the effectiveness and safety of their use in the treatment of perianal Crohn's disease based on available literature.


Sign in / Sign up

Export Citation Format

Share Document